Press release
Non-Cystic Fibrosis Bronchiectasis Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight
Non-Cystic Fibrosis Bronchiectasis companies working in the market are Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.Non-Cystic Fibrosis Bronchiectasis Market Summary
The NCFB market in the 7MM was valued at ~USD 1,455 million in 2023 and is projected to expand at a CAGR of 14.5% (2024-2034), driven by innovative therapies such as brensocatib and CMS I-neb, rising prevalence, and improved diagnostics. In 2023, there were ~1,028,651 diagnosed prevalent NCFB cases across the 7MM, with the US accounting for 37%, EU4+UK 54%, and Japan 9%. However, diagnostic complexity and frequent misdiagnosis remain key market barriers, delaying treatment and limiting therapy adoption. Additionally, the absence of disease-modifying therapies underscores a major unmet need, as current treatments mainly address symptoms. Leading players include Insmed, Aradigm, AstraZeneca, Bayer, and Grifols, all focusing on therapies targeting chronic airway inflammation and infection.
DelveInsight's "Non-Cystic Fibrosis Bronchiectasis Market Insights, Epidemiology, and Market Forecast - 2034" provides a comprehensive analysis of Non-Cystic Fibrosis Bronchiectasis (NCFB), including historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The report evaluates current treatment practices, emerging therapeutic options, market share of individual therapies, and the market size for NCFB from 2020 to 2034, segmented across the seven major markets (7MM). Additionally, it outlines treatment algorithms, key market drivers and barriers, unmet medical needs, and future opportunities, thereby offering a detailed assessment of the evolving NCFB therapeutic landscape.
Request for a Free Sample Report @ Non-Cystic Fibrosis Bronchiectasis Market Forecast [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some facts of the Non-Cystic Fibrosis Bronchiectasis Market Report are:
* According to DelveInsight, Non-Cystic Fibrosis Bronchiectasis market size is expected to grow at a decent CAGR by 2034.
* According to DelveInsight's analysis, the Non Cystic Fibrosis Bronchiectasis Market in the 7MM was valued at approximately USD 1,455.1 million in 2023. Over the forecast period from 2024 to 2034, this Non Cystic Fibrosis Bronchiectasis Market is projected to grow at a CAGR of 14.5%.
* Leading Non-Cystic Fibrosis Bronchiectasis companies working in the market are Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.
* Key Non-Cystic Fibrosis Bronchiectasis Therapies expected to launch in the market are Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others.
* The Non-Cystic Fibrosis Bronchiectasis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Non-Cystic Fibrosis Bronchiectasis pipeline products will significantly revolutionize the Non-Cystic Fibrosis Bronchiectasis market dynamics.
* In August 2025, the FDA approved Insmed's BRINSUPRI (brensocatib), the first oral therapy for non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years and older. Insmed has set the annual price at $88,000 before discounts.
* In February 2025, Insmed Incorporated announced that the FDA has accepted its New Drug Application (NDA) for brensocatib, intended for patients with non-cystic fibrosis bronchiectasis. The FDA granted Priority Review and set a target action date of August 12, 2025, under the Prescription Drug User Fee Act (PDUFA).
* In September 2024, Zambon released the results of the Phase III PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicine journal. The Phase III PROMIS-I trial demonstrated a significant reduction in pulmonary exacerbation rates. Although the PROMIS-II trial was terminated early due to the pandemic, pre-pandemic data showed consistency with PROMIS-I outcomes. Zambon is working with regulatory authorities to expedite patient access. The US FDA has granted CMS I-neb Breakthrough Therapy Designation (BTD), as well as QIDP and Fast Track Designation (FTD).
* In October 2024, Insmed shared positive late-breaking subgroup data from the Phase III ASPEN study of brensocatib for patients with NCFB at the CHEST 2024 Annual Meeting.
* On March 2024, Renovion announced results of a Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ARINA-1 in Adult Participants With Non-CF Bronchiectasis (NCFBE) With Excess Mucus and Cough.
* On February 2024, Haisco Pharmaceutical Group Co., Ltd announced results of a Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-cystic Fibrosis Bronchiectasis.
Non-Cystic Fibrosis Bronchiectasis Overview
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic respiratory condition characterized by irreversible dilation and inflammation of the bronchi, leading to recurrent respiratory infections, persistent cough, excessive mucus production, and progressive lung damage. Unlike cystic fibrosis-related bronchiectasis, NCFB occurs in the absence of cystic fibrosis mutations and may have different underlying causes and clinical manifestations. NCFB can result from various predisposing factors, including recurrent respiratory infections, airway obstruction, immunodeficiency, allergic bronchopulmonary aspergillosis, primary ciliary dyskinesia, and connective tissue disorders. In some cases, the etiology remains idiopathic. Diagnosis of NCFB involves a combination of clinical evaluation, pulmonary function tests, imaging studies (such as high-resolution computed tomography), and microbiological assessments of sputum samples to identify potential pathogens. Management of NCFB aims to alleviate symptoms, prevent exacerbations, and slow disease progression. Treatment strategies may include airway clearance techniques, bronchodilators, mucolytic agents, antibiotics for treating bacterial infections, inhaled corticosteroids, and, in severe cases, long-term oxygen therapy or surgical interventions such as bronchial artery embolization or lung transplantation.
Despite therapeutic interventions, NCFB remains a challenging condition associated with significant morbidity and mortality. Multidisciplinary management involving pulmonologists, respiratory therapists, physiotherapists, and other healthcare professionals is essential for optimizing outcomes and improving quality of life for patients with NCFB.
Do you know what will be the Non-Cystic Fibrosis Bronchiectasis market share in 7MM by 2034 - NCFB Market Dynamics and Trends [https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Non-Cystic Fibrosis Bronchiectasis Market Outlook
In 2023, the NCFB market size in the 7MM was approximately USD 1.46 billion, with the U.S. contributing USD 664.3 million (46%), EU4 and the UK accounting for USD 722.9 million, and Japan generating USD 67.8 million. Bronchodilators dominated market share at USD 1.01 billion. Leading companies such as Insmed, Zambon, AstraZeneca, Renovion, and Sanofi are actively advancing therapies, supporting a projected CAGR of 14.5% (2024-2034).
The Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment market is experiencing strong growth, driven by advances in pharmacological and non-pharmacological interventions targeting the disease's complex mechanisms. Current therapies include antibiotics, corticosteroids, bronchodilators, and mucolytics, with inhaled antibiotics proving effective in reducing chronic bacterial infections and exacerbations. Emerging drugs such as Brensocatib (DPP1 inhibitor) and BI 1291583 (cathepsin C inhibitor) are advancing treatment by addressing neutrophilic inflammation, while investigational agents like CMS I-neb, FASENRA, and Itepekimab target eosinophilic pathways. Non-drug approaches, especially Airway Clearance Techniques (ACTs), remain essential for mucus management and infection prevention.
Despite progress, challenges such as limited guidelines and underexplored therapies, including mucolytics and hyperosmolar agents, may hinder optimal outcomes. However, ongoing clinical trials highlight promising opportunities for innovative treatments that could significantly improve patient quality of life and reduce healthcare burdens.
Non-Cystic Fibrosis Bronchiectasis Epidemiology
According to DelveInsight, the diagnosed prevalent cases of Non-Cystic Fibrosis Bronchiectasis (NCFB) in the 7MM were ~1.03 million in 2023, a figure projected to rise through 2034 due to improved awareness, screening, and diagnostic advancements. The United States reported the highest burden with ~380,711 cases, while France had the lowest at ~37,576 cases.
Within the EU4 and the UK, the UK led with ~224,976 cases, followed by Spain (~149,236) and Italy (~89,584). Severity distribution in this region included ~235,481 moderate, ~163,649 severe, and ~152,230 mild cases. In the UK, females (~130,486) outnumbered males (~94,490).
In Japan, ~96,580 cases were reported in 2023, with idiopathic/unknown causes accounting for the majority (~32,837).
NCFB Epidemiology Segmentation:
* Non Cystic Fibrosis Bronchiectasis diagnosed prevalent cases
* Non Cystic Fibrosis Bronchiectasis severity-specific diagnosed prevalent cases
* Non Cystic Fibrosis Bronchiectasis gender-specific diagnosed prevalent cases
* Non Cystic Fibrosis Bronchiectasis etiology-specific diagnosed prevalent cases
* Microbiology of Non Cystic Fibrosis Bronchiectasis patients
Interested to know how the emerging diagnostic approaches will be contributing in increased Non-Cystic Fibrosis Bronchiectasis diagnosed prevalence pool? Download report - NCFB Patient Pool Forecast [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
NCFB Pipeline Development Activities and Drugs Uptake
Inhaled Colistimethate Sodium (CMS I-neb) - Zambon
CMS I-neb is an investigational inhaled therapy for NCFB patients colonized with P. aeruginosa , leveraging colistimethate sodium, a prodrug of colistin, to disrupt Gram-negative bacterial membranes, including drug-resistant strains. Phase III PROMIS-I showed a significant reduction in pulmonary exacerbations, while PROMIS-II, though halted early due to COVID-19, yielded consistent pre-pandemic data. The FDA has granted Breakthrough Therapy, QIDP, and Fast Track designations, with Zambon advancing regulatory discussions.
FASENRA (benralizumab) - AstraZeneca
FASENRA, an anti-IL-5 receptor alpha monoclonal antibody, depletes eosinophils via NK cell-mediated apoptosis. It is being evaluated for NCFB with eosinophilic inflammation (NCFB+EI). Phase III trials for this indication were completed in April 2024.
Non-Cystic Fibrosis Bronchiectasis Pipeline Development Activities
The Non-Cystic Fibrosis Bronchiectasis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Non-Cystic Fibrosis Bronchiectasis key players involved in developing targeted therapeutics.
* Brensocatib: Insmed/AstraZeneca
* Inhaled Colistimethate Sodium (CMS I-neb): Zambon
* FASENRA (benralizumab): AstraZeneca
* ARINA-1 (RVN-301): Renovion
* HSK31858: Haisco Pharmaceutical Group/Chiesi Farmaceutici S.p.A
* AP-PA02: Armata Pharmaceuticals
* Ensifentrine (Nebulizer): Verona Pharma
* Itepekimab: Sanofi/Regeneron Pharmaceuticals
* BI 1291583: Boehringer Ingelheim
* CHF 6333: Chiesi Farmaceutici S.p.A.
* CSL787: CSL
Download report to know which TOP 3 therapies will be capturing the largest Non-Cystic Fibrosis Bronchiectasis market share by 2034? Click here - NCFB Treatment Market [https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment
Major key companies are working proactively in the Non-Cystic Fibrosis Bronchiectasis Therapeutics market to develop novel therapies which will drive the Non-Cystic Fibrosis Bronchiectasis treatment markets in the upcoming years are Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.
Do you know how Brensocatib and Colistimethatesodium market launch will be impacting the Non-Cystic Fibrosis Bronchiectasis market CAGR? Download sample report - Non-Cystic Fibrosis Bronchiectasis Clinical Trials and Drugs Market [https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Non-Cystic Fibrosis Bronchiectasis Report Key Insights
1. Non-Cystic Fibrosis Bronchiectasis Patient Population
2. Non-Cystic Fibrosis Bronchiectasis Market Size and Trends
3. Key Cross Competition in the Non-Cystic Fibrosis Bronchiectasis Market
4. Non-Cystic Fibrosis Bronchiectasis Market Dynamics (Key Drivers and Barriers)
5. Non-Cystic Fibrosis Bronchiectasis Market Opportunities
6. Non-Cystic Fibrosis Bronchiectasis Therapeutic Approaches
7. Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis
8. Non-Cystic Fibrosis Bronchiectasis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Non-Cystic Fibrosis Bronchiectasis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Non-Cystic Fibrosis Bronchiectasis Competitive Intelligence Analysis
4. Non-Cystic Fibrosis Bronchiectasis Market Overview at a Glance
5. Non-Cystic Fibrosis Bronchiectasis Disease Background and Overview
6. Non-Cystic Fibrosis Bronchiectasis Patient Journey
7. Non-Cystic Fibrosis Bronchiectasis Epidemiology and Patient Population
8. Non-Cystic Fibrosis Bronchiectasis Treatment Algorithm, Current Treatment, and Medical Practices
9. Non-Cystic Fibrosis Bronchiectasis Unmet Needs
10. Key Endpoints of Non-Cystic Fibrosis Bronchiectasis Treatment
11. Non-Cystic Fibrosis Bronchiectasis Marketed Products
12. Non-Cystic Fibrosis Bronchiectasis Emerging Therapies
13. Non-Cystic Fibrosis Bronchiectasis Seven Major Market Analysis
14. Attribute Analysis
15. Non-Cystic Fibrosis Bronchiectasis Market Outlook (7 major markets)
16. Non-Cystic Fibrosis Bronchiectasis Access and Reimbursement Overview
17. KOL Views on the Non-Cystic Fibrosis Bronchiectasis Market
18. Non-Cystic Fibrosis Bronchiectasis Market Drivers
19. Non-Cystic Fibrosis Bronchiectasis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-market-outlook-2034-clinical-trials-market-size-medication-prevalence-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/partner-identification-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Cystic Fibrosis Bronchiectasis Market Outlook 2034 - Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight here
News-ID: 4168799 • Views: …
More Releases from ABNewswire

Next-generation Firewall Market Demand, Latest Trends, Outlook, Size, Share, App …
Next-generation Firewall Market by Offering (Hardware, Software, Services), Deployment Mode (On-premises, Cloud/Virtual), Organization Size (Large Enterprises, SMEs), Vertical (BFSI, Government, Other Verticals) and Region - Global Forecast to 2028
The size of the global Next-generation Firewall Market [https://www.marketsandmarkets.com/Market-Reports/next-generation-firewall-ngfw-market-32240698.html?utm_campaign=nextgenerationfirewallngfwmarket&utm_source=abnewswire.com&utm_medium=paidpr] is expected to increase at a Compound Annual Growth Rate (CAGR) of 11.4% from USD 5.0 billion in 2023 to USD 8.6 billion by 2028. Next-Generation Firewalls (NGFWs) are essential for complying with…

Logistics & Healthcare Use Cases Drive Embodied AI Market to USD 23.06 Billion b …
The global Embodied AI Market in terms of revenue is estimated to be worth $4.44 billion in 2025 and is poised to reach $23.06 billion by 2030, growing at a CAGR of 39.0% during the forecast period.
The report "Embodied AI Market [https://www.marketsandmarkets.com/Market-Reports/embodied-ai-market-83867232.html?utm_source=abnewswire.com&utm_medium=PaidPR&utm_campaign=embodiedaimarket] by Product Type [Robots (Humanoid Robots, Mobile Robots, Industrial Robots, Service Robots, Cobots), Exoskeletons, Autonomous Systems, Smart Appliances], Level of Embodiment (Level 1, Level 2, Level 3) -…

Global Postbiotics Market Set to Reach USD 224.8 Million by 2030, Growing at 8.9 …
Postbiotics Market by Source (Bacteria, Yeast), Application (Functional Food & Beverages, Dietary Supplements, Animal Feed, Cosmetics & Personal Care, and Pharmaceuticals), Form, Function, Manufacturing Technology, and Region - Global Forecast to 2030
The postbiotics market [https://www.marketsandmarkets.com/Market-Reports/postbiotics-market-237110254.html] is valued at USD 146.7 million in 2025 and is projected to reach USD 224.8 million by 2030, growing at a CAGR of 8.9%. Growth is being fueled by rising consumer awareness of the link…

Acrylic Resins Market Size, Competitor Ranking Analysis, Market Trend Forecast R …
The Acrylic Resins Market is growing steadily, driven by demand in coatings, construction, automotive, and electronics. Key players like BASF, Dow, Mitsubishi Chemical Group, Sumitomo Chemical, and Arkema are leading with innovative, durable, and eco-friendly resin solutions. Their global reach and strong R&D capabilities ensure sustainable advancements, meeting evolving industry needs across diverse end-use applications.
The acrylic resins market is projected to reach USD 28.55 billion by 2030 from USD 21.89…
More Releases for Bronchiectasis
Bronchiectasis Market Insights and Future Outlook
Introduction
Bronchiectasis, a chronic respiratory condition characterized by abnormal widening of the bronchi, leads to persistent cough, recurrent infections, and progressive lung damage. Once considered rare, it is now increasingly diagnosed due to better imaging technologies and rising global awareness. The condition significantly impacts patient quality of life and requires lifelong management.
The Bronchiectasis Market is gaining traction as healthcare systems invest in respiratory disease management, pharmaceutical companies develop advanced inhaled antibiotics,…
Non-Cystic Fibrosis Bronchiectasis Market Thrives On Surging Respiratory Disease …
The Non-Cystic Fibrosis Bronchiectasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Non-Cystic Fibrosis Bronchiectasis Market?
The non-cystic fibrosis bronchiectasis market has grown strongly, from $3.5 billion in 2024 to $3.74 billion in 2025 at a CAGR of 6.9%.…
Key Influencer in the Non-Cystic Fibrosis Bronchiectasis Market 2025: Non-Cystic …
What industry-specific factors are fueling the growth of the non-cystic fibrosis bronchiectasis market?
The rising prevalence of respiratory diseases is expected to drive the non-cystic fibrosis bronchiectasis market. Respiratory diseases, influenced by environmental pollution and lifestyle factors, are increasing. Non-cystic fibrosis bronchiectasis, a condition affecting the lungs, requires specialized treatments and interventions. A report published by the UK's Office for Health Improvement and Disparities in June 2023 showed a rise in…
Transforming the Non-Cystic Fibrosis Bronchiectasis Market in 2025: Non-Cystic F …
What Is the Expected Size and Growth Rate of the Non-Cystic Fibrosis Bronchiectasis Market?
The market size of non-cystic fibrosis bronchiectasis has significantly expanded in the past few years. It is projected to prosper from $3.5 billion in 2024 to $3.74 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.9%. The expansion in the previous interval is due to factors like increasing occurrence and prevalence, progressive advancements…
Bronchiectasis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Bronchiectasis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Bronchiectasis Research. Learn more about our innovative pipeline…
Bronchiectasis Global Market Research Report 2025
Bronchiectasis Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/bronchiectasis-market/80987
The report firstly introduced the Bronchiectasis basics: definitions, classifications, applications and market overview; product…